Searched for
GLENMARK ASTHMA DRUG
These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Delhi HC upholds injunction against Glenmark PharmaSun Pharma Laboratories, a wholly-owned subsidiary of Sun Pharmaceutical Industries, and Glenmark are contesting over their right to use dr...
- HC restrains Glenmark from selling asthma drug under 'Indamet' nameSun Pharma and Glenmark are contesting over their right to use drug names "Istamet" and "Indamet", respectively, which Sun Pharma finds to ...
- FDA okays Glenmark's first-in-human study for respiratory drugAccording to IMS sales data for the 12-month period ending February 2017, annual sales of XOLAIR 150 mg injection was approximately $1.7 bi...
- Glenmark Generics recalls anti-asthma drug from US marketGlenmark Generics is recalling from the US market multiple lots of Montelukast Sodium tablets (10 mg) on "off-odour" complaints.
- Aurobindo Pharma, Glenmark get FDA nod for generic montelukast sodium tabletsNew Delhi Drug firms Aurobindo Pharma and Glenmark have received approval from the US health regulator to manufacture and market generic mo...
- Aurobindo Pharma, Glenmark get USFDA nod for generic asthma drugAurobindo, Glenmark today said they have received approval from the US health regulator to manufacture, market generic montelukast tablets.
- Indian pharma companies like Aurobindo and Glenmark set to gain from USFDA nod for asthma drugIndian drug makers are set to benefit from a decision by the USFDA to allow sale of generic Singulair tablets used for treating asthma and ...
- Glenmark Pharmaceuticals receives USFDA tentative nod for anti-asthma tabletsGlenmark said it has received tentative approval from the US health regulator to market its tablets used for treating asthma and seasonal a...
- Glenmark starts Phase-IIb human trials of Revamilast moleculeGlenmark Pharmaceuticals on Wednesday said it has started Phase-IIb human trials of its 'Revamilast' molecule.
- Glenmark takes 17% knock, biggest in 2 monthsGlenmark, one of the top 10 pharma companies in India by market capitalisation, witnessed a sharp fall of 17% in its intra-day stock price ...
- Glenmark seeks action against govt hospital for falsifying dataGlenmark Pharmaceuticals has complained to the drug regulator that the government-funded research centre, Guru Govind Singh Hospital in Jam...
- Glenmark gets $15 mn milestone payment from Forest LabsAfter a long wait, Glenmark Pharma has finally received a second milestone payment of $15 million from Forest Laboratories for its asthma e...
- Glenmark gets domestic patent for NCEIn what is perhaps the first domestic patent for a new chemical entity (NCE) by an Indian company, drug research company Glenmark Pharmaceu...
- Glenmark soars on likely deal of $150 mnMarket participants expect payout to Glenmark from such a deal would include upfront and milestone payments and royalties on sales.
- Glenmark gets US nod for drug trialsEnding a long wait for Glenmark Pharmaceuticals, the US Food and Drug Administration (FDA) finally gave its nod to the Indian drugmaker to ...
- Glenmark to enter Europe with Rs 100 crore buyLeading mid-sized pharma company Glenmark Pharmaceuticals would soon enter the European market by acquiring a front-end pharmaceutical comp...
- Glenmark's asthma molecule trials crawl onGlenmark Pharmaceuticals’ much-hyped asthma research molecule Oglemilast (code name GRRC 3886), is witnessing slower clinical progress, put...
- Milestone for GlenmarkGlenmark’s out-licensing deal with the German pharma major, Merck KGaA, for its diabetes molecule, a DPP-IV inhibitor, is an important mile...
Load More
